These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Flunarizine and cinnarizine-induced parkinsonism: 25 years of de Melo-Souza's syndrome. Teive HA; Munhoz RP; Ferraz HB Arq Neuropsiquiatr; 2009 Sep; 67(3B):957. PubMed ID: 19838540 [No Abstract] [Full Text] [Related]
8. [Antiepileptic action of Ca antagonist, flunarizine]. Otomo E Nihon Rinsho; 1989 Aug; 47(8):1842-6. PubMed ID: 2585749 [No Abstract] [Full Text] [Related]
9. Iatrogenic parkinsonism: the role of flunarizine and cinnarizine. Miguel R; Correia AS; Bugalho P J Parkinsons Dis; 2014; 4(4):645-9. PubMed ID: 25125483 [TBL] [Abstract][Full Text] [Related]
11. Calcium-entry blockers-induced parkinsonism: possible role of inherited susceptibility. Negrotti A; Calzetti S; Sasso E Neurotoxicology; 1992; 13(1):261-4. PubMed ID: 1508427 [TBL] [Abstract][Full Text] [Related]
12. Extrapyramidal symptoms associated with calcium-channel blockers. Daniel JR; Mauro VF Ann Pharmacother; 1995 Jan; 29(1):73-5. PubMed ID: 7711350 [TBL] [Abstract][Full Text] [Related]
13. Extrapyramidal symptoms after exposure to calcium channel blocker-flunarizine or cinnarizine. Jhang KM; Huang JY; Nfor ON; Tung YC; Ku WY; Lee CT; Liaw YP Eur J Clin Pharmacol; 2017 Jul; 73(7):911-916. PubMed ID: 28386684 [TBL] [Abstract][Full Text] [Related]
14. A long-term follow-up study of cinnarizine- and flunarizine-induced parkinsonism. Negrotti A; Calzetti S Mov Disord; 1997 Jan; 12(1):107-10. PubMed ID: 8990063 [TBL] [Abstract][Full Text] [Related]
15. [Increase in Parkinson symptoms caused by calcium antagonists]. Hefner R; Fischer PA Nervenarzt; 1989 Mar; 60(3):187-8. PubMed ID: 2654677 [No Abstract] [Full Text] [Related]
16. Parkinsonism and other movement disorders in outpatients in chronic use of cinnarizine and flunarizine. Fabiani G; Pastro PC; Froehner C Arq Neuropsiquiatr; 2004 Sep; 62(3B):784-8. PubMed ID: 15476069 [TBL] [Abstract][Full Text] [Related]
17. [Calcium channel blockers in therapy of neurologic diseases]. Wessely P; Wöber-Bingöl C Wien Med Wochenschr; 1993; 143(19-20):514-8. PubMed ID: 8135034 [TBL] [Abstract][Full Text] [Related]
18. Flunarizine and the risk of parkinsonism in a newly diagnosed type 2 diabetic population in Taiwan: A nested case-control study. Liang CY; Yeh YC; Lee CJ; Chen YY J Clin Neurosci; 2018 Apr; 50():281-286. PubMed ID: 29396059 [TBL] [Abstract][Full Text] [Related]
19. [A comparative study of the effectiveness of topiramate and flunarizine in independent series of chronic migraine patients without medication abuse]. Gracia-Naya M; Ríos C; García-Gomara MJ; Sánchez-Valiente S; Mauri-Llerda JÁ; Santos-Lasaosa S; Artal-Roy J; Latorre-Jiménez AM Rev Neurol; 2013 Oct; 57(8):347-53. PubMed ID: 24081889 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of topical 0.05% flunarizine in patients with open-angle glaucoma or ocular hypertension-a pilot study. Mansouri K; Silva SE; Shaarawy T J Glaucoma; 2011 Oct; 20(8):519-22. PubMed ID: 21048514 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]